|
Volumn 54, Issue 5, 2002, Pages 1299-1301
|
Tumor hypoxia is important in radiotherapy, but how should we measure it?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
2 (2 NITRO 1H IMIDAZOL 1 YL) N (2,2,3,3,3 PENTAFLUOROPROPYL)ACETAMIDE;
CARBONIC ANHYDRATASE 9;
LYASE;
NITROIMIDAZOLE DERIVATIVE;
PIMONIDAZOLE;
TRANSCRIPTION FACTOR;
TUMOR MARKER;
UNCLASSIFIED DRUG;
CANCER RADIOTHERAPY;
CANCER SURGERY;
CELL HYPOXIA;
CELL INVASION;
CORRELATION ANALYSIS;
DISEASE COURSE;
EDITORIAL;
HEAD TUMOR;
HISTOCHEMISTRY;
HUMAN;
HYPOXEMIA;
HYPOXIC CELL;
IMMUNOHISTOCHEMISTRY;
MEASUREMENT;
NECK TUMOR;
OXYGEN ELECTRODE;
OXYGENATION;
PRIORITY JOURNAL;
PROTEIN BLOOD LEVEL;
QUANTITATIVE ASSAY;
RADIOSENSITIVITY;
SOLID TUMOR;
STAINING;
STANDARD;
SUPERFICIAL CANCER;
TISSUE NECROSIS;
TISSUE OXYGENATION;
TREATMENT OUTCOME;
TUMOR BIOPSY;
TUMOR BLOOD FLOW;
TUMOR CELL;
TUMOR RESISTANCE;
CELL HYPOXIA;
ELECTRODES;
HEAD AND NECK NEOPLASMS;
HUMANS;
HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT;
NEOPLASMS;
OXYGEN;
TRANSCRIPTION FACTORS;
|
EID: 0036890714
PISSN: 03603016
EISSN: None
Source Type: Journal
DOI: 10.1016/S0360-3016(02)03936-6 Document Type: Editorial |
Times cited : (33)
|
References (4)
|